MediWound Ltd. (MDWD) Releases Quarterly Earnings Results, Hits Expectations
MediWound Ltd. (NASDAQ:MDWD) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.26) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.26). MediWound had a negative return on equity of 103.14% and a negative net margin of 2,332.07%. The business earned $0.52 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The company’s quarterly revenue was up 420.0% compared to the same quarter last year.
Shares of MediWound (NASDAQ:MDWD) opened at 5.80 on Monday. The stock’s market capitalization is $126.73 million. MediWound has a 12-month low of $5.25 and a 12-month high of $10.47. The firm’s 50-day moving average price is $6.83 and its 200 day moving average price is $7.50.
Several equities research analysts have recently commented on the company. Zacks Investment Research upgraded MediWound from a “sell” rating to a “hold” rating in a research note on Wednesday, October 26th. Jefferies Group cut their price target on MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, July 29th. Finally, Wells Fargo & Co. began coverage on MediWound in a research note on Wednesday, August 17th. They set an “outperform” rating and a $14.00 price target for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. MediWound currently has an average rating of “Buy” and a consensus target price of $13.63.
A hedge fund recently raised its stake in MediWound stock. Morgan Stanley raised its stake in shares of MediWound Ltd. (NASDAQ:MDWD) by 91,055.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 182,311 shares of the biopharmaceutical company’s stock after buying an additional 182,111 shares during the period. Morgan Stanley owned about 0.83% of MediWound worth $1,404,000 as of its most recent SEC filing. 26.67% of the stock is owned by hedge funds and other institutional investors.
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.